Navigation Links
Osseon® Announces Commercial Release of Osseoflex®SN (Steerable Needle)
Date:9/1/2011

SANTA ROSA, Calif., Sept. 1, 2011 /PRNewswire/ -- Today, Osseon® Therapeutics, Inc. launched the Osseoflex®SN (steerable needle). Osseoflex SN is the newest in Osseon's suite of minimally invasive products for treatment of spinal compression fractures.

(Photo:  http://photos.prnewswire.com/prnh/20110901/SF61461)

The Osseoflex SN allows direct unipedicular access to the entire vertebral body. The Osseoplasty™ procedure offers unparalleled flexibility and control for percutaneous vertebral augmentation, cement delivery, and fracture stabilization, resulting in significant pain relief for most patients within the same day.

"Osseoflex SN is the next generation of steerable, minimally invasive cement delivery devices for the treatment of osteoporosis and related bone diseases and injuries. Our technology for vertebral compression fracture treatment offers increased precision, less operating time for physicians and decreased risk for patients," said John Stalcup, Ph.D., Osseon's CEO and President.

Osseon Therapeutics currently markets Osseoflex®SN (steerable needle), Osseoperm® (bone cement), Osseoflex®DR (steerable bone drill), Osseoflex®BT (steerable bone tamp), and Osseoflex®Access (bone access kit). Together, Osseon's suite of products provides groundbreaking biomedical devices for physicians who treat vertebral compression fractures due to osteoporosis, myeloma, and acute osteo-traumatic injuries.

About Osseon

Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery systems provide efficacy and safety competitive with all other commercial solutions, while delivering superior efficiency and cost. By improving the treatment of compression fractures within the entire thoracic and lumbar spine, Osseon offers alternative solutions to symptomatic patients as well as to the physicians and medical facilities that treat them. Osseon's products have received both FDA clearance and the CE Mark for product distribution in the United States and the European Union.

For more information, visit our website at www.osseon.com.


'/>"/>
SOURCE Osseon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
2. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
3. PTCB Board of Governors Announces Executive Director/CEO Murer Corrigan to Leave Organization
4. Hill-Rom Announces Fourth Quarter 2011 Dividend
5. Volcano Corporation Announces Presentations at Upcoming Investor Conferences
6. Sequenom Announces Participation at William Blair and Company 5th Annual Emerging Growth Stock Conference
7. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
8. Concord Medical Services Announces the Appointment of Mr. Adam Sun as Acting Chief Financial Officer
9. Ambry Genetics Announces Launch of Their CancerArray™ Product and Services Utilizing aCGH Technology
10. ORTHOCON Announces Signing of Exclusive, Worldwide License Agreement With Bezwada Biomedical
11. Caliper Life Sciences Announces IVIS Spectrum CT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... it’s been named Agency of Record (AOR) for Theravent, Inc. , the ... snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand distribution ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover ... O2X , an active lifestyle company that provides Human Performance Training and ... firefighters, police offers, first responders, military officers and others in service through the ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Alive for ... who wish to overcome their mental health struggles. The Alive team uses advanced ... says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... 21, 2017 , ... Northern California Medical Associates ... Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference plays ... an opportunity to learn about cutting edge treatments, to collaborate, share research and ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... practices, is seeking candidates to serve on its Accreditation and Standards Committees ... “RadSite’s ultimate mission is improving image quality and reducing patient radiation dose,” ...
Breaking Medicine News(10 mins):